Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
Third Harmonic Bio’s $213.1 Million IPO
GitLab’s $800 Million Initial Public Offering
Fenwick represented GitLab Inc. on the deal, while Latham & Watkins represented the underwriters. GitLab Inc. (Nasdaq: GTLB), provider of The DevOps Platform, announced its initial public...
Impel NeuroPharma’s $80 Million Initial Public Offering
Fenwick & West LLP advised Impel NeuroPharma on the deal. Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its...



























